SG Americas Securities’s Regenxbio RGNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$166K Sell
19,847
-20,684
-51% -$217K ﹤0.01% 2724
2025
Q4
$584K Buy
40,531
+13,931
+52% +$174K ﹤0.01% 2403
2025
Q3
$257K Buy
+26,600
New +$235K ﹤0.01% 2589
2025
Q1
Sell
-10,375
Closed -$80K 3707
2024
Q4
$80K Sell
10,375
-3,570
-26% -$33.5K ﹤0.01% 2800
2024
Q3
$146K Buy
+13,945
New +$170K ﹤0.01% 2760
2024
Q1
Sell
-30,813
Closed -$553K 3362
2023
Q4
$553K Buy
+30,813
New +$543K 0.01% 1414
2023
Q1
Sell
-5,035
Closed -$114K 3503
2022
Q4
$114K Sell
5,035
-4,957
-50% -$112K ﹤0.01% 2635
2022
Q3
$264K Sell
9,992
-21,138
-68% -$627K ﹤0.01% 2098
2022
Q2
$769K Buy
31,130
+10,704
+52% +$267K 0.01% 1549
2022
Q1
$678K Sell
20,426
-12,581
-38% -$349K 0.01% 1694
2021
Q4
$1.08M Sell
33,007
-712
-2% -$24.2K 0.01% 1595
2021
Q3
$1.41M Buy
+33,719
New +$1.21M 0.01% 1599
2021
Q2
Sell
-21,033
Closed -$717K 3176
2021
Q1
$717K Buy
21,033
+18,133
+625% +$773K ﹤0.01% 1761
2020
Q4
$132K Sell
2,900
-78,684
-96% -$2.75M ﹤0.01% 2897
2020
Q3
$2.25M Buy
81,584
+71,974
+749% +$2.35M 0.01% 679
2020
Q2
$354K Buy
9,610
+1,747
+22% +$65.1K ﹤0.01% 2394
2020
Q1
$255K Sell
7,863
-438
-5% -$18.2K ﹤0.01% 2344
2019
Q4
$340K Sell
8,301
-45,822
-85% -$1.81M ﹤0.01% 2095
2019
Q3
$1.93M Buy
54,123
+42,982
+386% +$1.74M 0.02% 986
2019
Q2
$572K Sell
11,141
-168,138
-94% -$8.39M ﹤0.01% 1802
2019
Q1
$10.3M Buy
179,279
+169,571
+1,747% +$8.4M 0.09% 215
2018
Q4
$407K Buy
9,708
+6,286
+184% +$369K ﹤0.01% 1999
2018
Q3
$258K Buy
3,422
+931
+37% +$67.1K ﹤0.01% 2444
2018
Q2
$179K Buy
+2,491
New +$119K ﹤0.01% 2674
2018
Q1
Sell
-24,116
Closed -$802K 3495
2017
Q4
$802K Buy
24,116
+5,339
+28% +$161K 0.01% 1532
2017
Q3
$619K Buy
+18,777
New +$423K 0.01% 1654
2017
Q2
Sell
-31,686
Closed -$612K 3447
2017
Q1
$612K Buy
+31,686
New +$611K 0.01% 1708

Other funds holding RGNX

SG Americas Securities's RGNX Position: Q1 2026 in Review

SG Americas Securities reduced its Regenxbio (RGNX) stake by 51% in Q1 2026, selling an estimated $217K and leaving 19,847 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #2724.

SG Americas Securities first reported a position in RGNX in Q1 2017 and has held it in 27 quarters since. The position peaked at $10.3M in Q1 2019. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

  • SG Americas Securities held 19,847 shares of Regenxbio worth $166K as of Q1 2026.
  • SG Americas Securities sold 20,684 Regenxbio shares in Q1 2026, an estimated $217K.
  • Regenxbio made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #2724 holding.
  • SG Americas Securities first reported a position in Regenxbio in Q1 2017 and has held it in 27 quarters since.
  • SG Americas Securities's Regenxbio position peaked at $10.3M in Q1 2019.
  • 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.